GPCR Structure Corp Total Debt to Capital

Corporate emblem and logo of Structure Therapeutics (GPCR)

Structure Therapeutics develops pills for diabetes and obesity using computational receptor analysis, while the debt-to-equity ratio on the current GURU.Markets system chart contains a critical signal, where the 0.00 level serves as a key benchmark. A virtual management model with outsourced trials mitigates risks, yet business success remains dependent on clinical results and external funding.

GPCR: Structure Therapeutics Inc. Total Debt to Capital 04/28/2023 - 10/28/2026
Brand item of Structure Corp

The total debt-to-equity ratio determines the extent of a company's reliance on borrowed funds relative to its own resources. By analyzing the total liabilities-to-equity chart, an investor assesses the stability of financial leverage. This metric compares aggregate credit obligations with the net value of assets to identify default risks. For Structure Therapeutics (GPCR), a low debt load is critically important, as the development of obesity drugs depends on the success of trials rather than market conditions. Controlling borrowings ensures the survival of the biotech startup amidst high industry competition.

Key competitors

Debt to Equity Ascendis Pharma ASND|Aggregate Debt to Equity Madrigal Pharmaceuticals Inc|Corcept (CORT) - Total Debt to Capital|All Debt to Shareholders' Equity Ratio Rhythm Corp (RYTM)|Total Debt to Capital AKRO (Akero Therapeutics)|metsera.com - Total Debt to Capital|Debt to Equity MoonLake (MLTX)|CRNX: All Debt to Shareholders' Equity Ratio|NAMS (NewAmsterdam Pharma N.V.) - Debt to Equity|Soleno Therapeutics Corp (SLNO) - Total Debt to Equity Ratio|FOLD (Amicus Therapeutics) - Total Debt to Capital|Total Debt to Capital 89bio.com (ETNB)|Agios Pharmaceuticals, Inc. (AGIO) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio MDXG (MiMedx Group Inc)|Rezolute Corp - Debt to Equity|Total Debt to Equity Ratio Lexicon Corp LXRX|MBX (MBX Biosciences Inc) - Total Debt to Capital|altimmune.com (ALT) - Debt to Capital|AARD - Total Debt to Equity Ratio|Sagimet Biosciences, Inc. (SGMT) - Aggregate Debt to Capital|BIOA (BioAge Labs Inc.) - Total Debt to Capital|Total Debt to Capital Biomea Fusion Corp|Total Debt to Capital Quince Therapeutics (QNCX)|Debt to Equity GUTS (fractyl.com)|VTVT: Debt to Equity|Agape ATP Corp - Debt to Capital|PLUR - Debt to Equity|SYBX - Debt to Equity|Lipocine Inc. - Total Debt to Capital|MTNB (Matinas BioPharma Holdings) - Total Debt to Capital Coefficient|SPRB: Debt to Equity|Total Debt to Capital Coefficient GLTO|Debt to Equity CTCX (Carmell Corp)|Total Debt to Equity Ratio LUMO (Lumos Therapeutics)|Debt to Equity ONVO|RDUS - Total Debt to Capital Coefficient